Anti-Bub1 antibody [2F9]
5
(1 Review)
|
(42 Publications)
Mouse Monoclonal BUB1 antibody. Suitable for Flow Cyt and reacts with Human samples. Cited in 42 publications. Immunogen corresponding to Recombinant Fragment Protein within Human BUB1 aa 1-150.
View Alternative Names
BUB1L, BUB1, Mitotic checkpoint serine/threonine-protein kinase BUB1, hBUB1, BUB1A
- Flow Cyt
Unknown
Flow Cytometry - Anti-Bub1 antibody [2F9] (AB54893)
Overlay histogram showing HeLa cells stained with ab54893 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab54893, 1μg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2μg/1x106 cells ) used under the same conditions. Acquisition of >5,000 events was performed.
This image was generated using the ascites version of the product.
- ICC/IF
CiteAb
Immunocytochemistry/ Immunofluorescence - Anti-Bub1 antibody [2F9] (AB54893)
Immunocytochemistry-immunofluorescence using Anti-Bub1 antibody [2F9], ab54893. Publication image from Nilsson, J. et al., 2015, Nat Commun, 26031201. Legend direct from paper.
ZW10 kinetochore localization is not supported by a KNL1 fragment containing the Zwint binding domain.(a) Outline of the synchronization protocol used in this study. Cells were fixed 2 h after addition of nocodazole. (b) Schematic of human KNL1 with functional regions indicated. The region encoded by KNL1 1,834–2,316 and KNL1 1,834–2,316+4XMELT is depicted below. (c) HeLa cells were treated with a control RNAi oligo (luciferase) or an RNAi oligo targeting KNL1 for 48 h and arrested in mitosis using nocodazole for 2 h. In one condition, cells were co-transfected with a plasmid encoding KNL1 1,834–2,316-Venus as indicated. Cells were fixed and stained with DAPI, CREST (centromere marker) and Zwint. We used Bub1 as a KNL1 depletion marker because both our KNL1 and Zwint antibodies are rabbit polyclonal. Bub1 solely depends on KNL1 for its localization and its kinetochore levels follow KNL1. The expression of KNL1 1,834–2,316 Venus was detected by staining cells with a GFP antibody. (d,e) The kinetochore levels of Bub1 and Zwint were determined in the indicated conditions and normalized to CREST. (f,g) As in c–e, but cells were stained with a ZW10 antibody and the kinetochore levels of ZW10 were measured and normalized to CREST in the indicated conditions. At least 160 single kinetochores from eight different cells were measured in all the conditions and the mean with standard error of mean is indicated. Scale bar, 5 µm.
- ICC/IF
CiteAb
Immunocytochemistry/ Immunofluorescence - Anti-Bub1 antibody [2F9] (AB54893)
Immunocytochemistry-immunofluorescence using Anti-Bub1 antibody [2F9], ab54893. Publication image from Nilsson, J. et al., 2015, Nat Commun, 26031201. Legend direct from paper.
A region encompassing CD1 in Bub1 is required for RZZ localization.(a) Schematic of Bub1 primary structure with motifs indicated and below a schematic of the different truncation constructs used in this study. All constructs contain the Bub3 binding site ensuring kinetochore targeting. (b) HeLa cells were depleted of endogenous Bub1 using RNAi and the indicated Bub1 constructs were co-transfected for 48 h and cells were arrested with nocodazole for 2 h. Cells were fixed and stained for Bub1, CREST and ZW10. (c,d) The Bub1 (c) or ZW10 (d) kinetochores levels was measured and normalized to CREST signals. At least 160 single kinetochores were analysed from eight different cells and the mean with standard error of mean is indicated. A t-test was used to compare the values in d. (NS, not significant (P>0.05), *P≤0.05, **P≤0.01, ****P≤0.0001). Scale bar, 5 µm.
- ICC/IF
CiteAb
Immunocytochemistry/ Immunofluorescence - Anti-Bub1 antibody [2F9] (AB54893)
Immunocytochemistry-immunofluorescence using Anti-Bub1 antibody [2F9], ab54893. Publication image from Nilsson, J. et al., 2015, Nat Commun, 26031201. Legend direct from paper.
Bub1 is required for RZZ localization to kinetochores.(a) HeLa cells were depleted of endogenous KNL1 using RNAi and the indicated KNL1 constructs were co-transfected for 48 h and cells were arrested with nocodazole for 2 h. Cells were fixed and stained for GFP (KNL1 constructs), CREST and ZW10. (b) The ratios of ZW10/CREST and GFP/CREST signal were calculated. (c) As in a with the ZW10/CREST ratio shown in d. The GFP/CREST values for the three KNL1 constructs were : KNL1 1,834–2,316 : 1.00; KNL1 1,834–2,316+4XMELT : 1.11; KNL1 1,834–2,316 4XMELA : 0.85. (e) HeLa cells were treated with luciferase, BubR1 or Bub1 RNAi for 48 h and cells were arrested with nocodazole for 2 h. Cells were fixed and stained for Bub1, BubR1, CREST and ZW10 as indicated. (f) The kinetochore levels of ZW10 were measured and normalized to CREST and at least 160 single kinetochores from eight different cells was measured in all the conditions and the mean with standard error of mean is indicated. Scale bar, 5 µm.
- ICC/IF
CiteAb
Immunocytochemistry/ Immunofluorescence - Anti-Bub1 antibody [2F9] (AB54893)
Immunocytochemistry-immunofluorescence using Anti-Bub1 antibody [2F9], ab54893. Publication image from Nilsson, J. et al., 2015, Nat Commun, 26031201. Legend direct from paper.
The central region of Bub1 is required for RZZ recruitment.(a) Schematic of Bub1 primary structure with motifs indicated and below a schematic of different deletion and mutation constructs used in this study. All Bub1 constructs contain the Bub3 binding site ensuring kinetochore targeting. (b) HeLa cells were depleted of endogenous Bub1 using RNAi and the indicated Bub1 constructs were co-transfected for 48 h and cells were arrested with nocodazole for 2 h. Cells were fixed and stained for Bub1, CREST and ZW10. The expression of the exogenous Bub1 construct could be detected by the Bub1 antibody that recognize an epitope in the N terminus of Bub1 except for Bub1 δ1–146. *To detect Bub1 δ1–146 expression cells were stained with a GFP antibody. To determine if Bub1 δ1–146 could recruit ZW10 to kinetochores it was compared with cells expressing wild-type Bub1-Venus at a GFP signal level at which wild-type Bub1 could fully rescue ZW10 localization. The Venus levels were normalized to wild-type Bub1-Venus levels (set to 1) and incorporated into c. (c,d) The Bub1 (c) or ZW10 (d) intensity at kinetochores was measured and normalized to CREST. At least 160 single kinetochores were analysed from eight different cells and the mean with standard error of mean is indicated. Scale bar, 5 µm.
- ICC/IF
CiteAb
Immunocytochemistry/ Immunofluorescence - Anti-Bub1 antibody [2F9] (AB54893)
Immunocytochemistry-immunofluorescence using Anti-Bub1 antibody [2F9], ab54893. Publication image from Nilsson, J. et al., 2015, Nat Commun, 26031201. Legend direct from paper.
ZW10 kinetochore localization is not supported by a KNL1 fragment containing the Zwint binding domain.(a) Outline of the synchronization protocol used in this study. Cells were fixed 2 h after addition of nocodazole. (b) Schematic of human KNL1 with functional regions indicated. The region encoded by KNL1 1,834–2,316 and KNL1 1,834–2,316+4XMELT is depicted below. (c) HeLa cells were treated with a control RNAi oligo (luciferase) or an RNAi oligo targeting KNL1 for 48 h and arrested in mitosis using nocodazole for 2 h. In one condition, cells were co-transfected with a plasmid encoding KNL1 1,834–2,316-Venus as indicated. Cells were fixed and stained with DAPI, CREST (centromere marker) and Zwint. We used Bub1 as a KNL1 depletion marker because both our KNL1 and Zwint antibodies are rabbit polyclonal. Bub1 solely depends on KNL1 for its localization and its kinetochore levels follow KNL1. The expression of KNL1 1,834–2,316 Venus was detected by staining cells with a GFP antibody. (d,e) The kinetochore levels of Bub1 and Zwint were determined in the indicated conditions and normalized to CREST. (f,g) As in c–e, but cells were stained with a ZW10 antibody and the kinetochore levels of ZW10 were measured and normalized to CREST in the indicated conditions. At least 160 single kinetochores from eight different cells were measured in all the conditions and the mean with standard error of mean is indicated. Scale bar, 5 µm.
Reactivity data
Product details
Properties and storage information
Form
Purity
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Bub1 protein acts as a serine/threonine-protein kinase that is essential for proper chromosome segregation. It forms part of the spindle checkpoint complex along with other proteins such as BubR1 and Mad2. This complex ensures that chromosomes are correctly attached to the spindle microtubules before anaphase begins. Bub1's kinase activity contributes to the prevention of premature anaphase onset thereby helping maintain genomic stability.
Pathways
Bub1 is significantly involved in the mitotic checkpoint pathway and the cell cycle control pathway. Within these pathways Bub1 interacts closely with proteins like CDC20 and APC/C which are integral parts of the anaphase-promoting complex. Bub1 modifies the activity of these proteins to delay anaphase onset until all chromosomes are properly aligned ensuring the fidelity of cell division.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (42)
Recent publications for all applications. Explore the full list and refine your search
Communications biology 7:1473 PubMed39516273
2024
Applications
Unspecified application
Species
Unspecified reactive species
Molecular biology of the cell 35:ar141 PubMed39356777
2024
Applications
Unspecified application
Species
Unspecified reactive species
Communications biology 7:164 PubMed38337031
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nature 617:154-161 PubMed37100900
2023
Applications
Unspecified application
Species
Unspecified reactive species
Journal of molecular cell biology 14: PubMed36441015
2022
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of cell biology 221: PubMed35486148
2022
Applications
Unspecified application
Species
Unspecified reactive species
EMBO reports 23:e54171 PubMed35384228
2022
Applications
Unspecified application
Species
Unspecified reactive species
The EMBO journal 41:e110411 PubMed35373361
2022
Applications
Unspecified application
Species
Unspecified reactive species
STAR protocols 2:100774 PubMed34841272
2021
Applications
Unspecified application
Species
Unspecified reactive species
Cell reports 36:109740 PubMed34551298
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com